Published in final edited form as:

Psychiatry Res. 2019 May ; 275: 196–203. doi:10.1016/j.psychres.2019.03.016.

Childhood temperament is associated with distress, anxiety and reduced quality of life in schizophrenia spectrum disorders

Brandee Feola^a, Kristan Armstrong^a, Neil D. Woodward^a, Stephan Heckers^a, Jennifer Urbano Blackford^{a,b}

^aDepartment of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center

^bResearch Service, Tennessee Valley HealthCare System, US Department of Veterans Affairs

Abstract

Schizophrenia is conceptualized as a neurodevelopmental disorder and pre-morbid differences in social function and cognition have been well-established. Less is known about pre-morbid temperament and personality. Inhibited temperament—the predisposition to respond to novelty with wariness, fear, or caution—is a premorbid risk factor for anxiety, depression, and substance use but is understudied in schizophrenia. Participants were patients with schizophrenia spectrum disorders ($n = 166$) and healthy controls ($n = 180$). Patients completed measures of childhood inhibited temperament, clinical symptoms (anxiety, depression, PANSS factors), and quality of life. Patients had significantly higher levels of inhibited temperament relative to healthy controls. In patients with schizophrenia, higher inhibited temperament was significantly associated with co-morbid anxiety disorders, greater anxiety and depression symptoms, higher PANSS Distress scores, lower PANSS Excitement scores, and lower quality of life. The current findings replicate and extend previous research with a larger sample and are consistent with vulnerability in an affective path to psychosis. In schizophrenia, higher inhibited temperament was associated with a cluster of mood and anxiety symptoms. Inhibited temperament was not associated with psychosis symptoms. Patients with high inhibited temperament may especially benefit from treatments that specifically target anxiety and depression.

Keywords

psychosis; anxiety; depression; social anxiety; personality

1. Introduction

Schizophrenia has been conceptualized as a neurodevelopmental disorder (Murray and Lewis, 1987) based on evidence of early deviations from typical development in individuals who later develop schizophrenia. Pre-morbid differences in social functioning (Tarbox and Pogue-Geile, 2008) and cognitive abilities (Mollon and Reichenberg, 2018; Trotta et al., 2015) are commonly observed in schizophrenia. Later development of schizophrenia can be predicted by observations of social functioning in early home videos (Walker and Lewine,

1990) and teacher ratings of social functioning in childhood (Tsuji et al., 2013). Similarly, individuals who later developed schizophrenia showed a pattern of lower educational achievement and lower levels of academic functioning, as measured by standardized scores, at grade 11 (Fuller et al., 2002). Pre-morbid differences in personality have received less attention, but initial evidence suggests that the personality trait of high levels of neuroticism predicts later schizophrenia (Van Os and Jones, 2001; Lönngqvist et al., 2009). While pre-morbid differences in social functioning, cognition, and personality have often been considered to be general antecedent factors, the substantial heterogeneity in schizophrenia (Carpenter and Kirpatrick, 1988; Tandon et al., 2013) raises the question of whether the pre-morbid factors characterize all patients with schizophrenia or identify specific subgroups with altered neurodevelopmental trajectories. For example, several studies have identified cognitive subgroups. Combining measures of pre-morbid and current neuropsychological function reveals three patterns: intact functioning; deteriorated function, defined by typical pre-morbid function and current impairment; and compromised function, defined by impaired pre-morbid and current function (Weickert et al., 2000; Woodward and Heckers, 2015). The compromised subgroup has a distinct profile of reduced intracranial volume, relative to the other subgroups, suggestive of disrupted early cerebral development. Thus, it may be beneficial to identify other pre-morbid factors that account for variability in schizophrenia and may identify subgroups that emerge early in development.

A promising pre-morbid factor to consider is inhibited temperament. Temperament is defined as early-emerging and biologically-based individual differences in emotion, cognition, and behavior that interact with the environment to form adult personality. While pre-morbid personality differences have been observed in late adolescents (Van Os and Jones, 2001) and young adults (Lönngqvist et al., 2009), little is known about early-emerging temperament traits in people who later develop schizophrenia. Of the various temperament traits, one of the most fundamental individual differences is the tendency to approach or avoid novelty (Kagan et al., 1984). This trait—inhibited temperament—can be measured along a continuum ranging from individuals who are outgoing, bold, and fearless to individuals who are shy, cautious, and fearful when they encounter an unfamiliar or unexpected person, place, or object. Inhibited temperament is observable during the first year of life (Calkins, Fox and Marshall, 1996; Kagan, Snidman and Arcus, 1998), moderately stable across development (Robinson et al., 1992; Dilalla, Kagan and Reznick, 1994; Smith et al., 2012), and heritable (Dilalla et al., 1994; Eley et al., 2003; Robinson et al., 1992). Childhood inhibited temperament confers risk for the development of anxiety disorders (Hirshfeld et al., 1992; Biederman et al., 1993; Schwartz, Snidman and Kagan, 1999; Chronis-Tuscano et al., 2009; Essex et al., 2010; Hirshfeld-Becker et al., 2010; Biederman et al., 2001); a meta-analysis of longitudinal studies found that almost half of inhibited children, a 7-fold increase in odds, developed social anxiety disorder by adolescence. Childhood inhibited temperament is also associated with an increased risk for the development of depression (Beesdo et al., 2007; Gladstone et al., 2005; Gladstone and Parker, 2006; Neal et al., 2002). For example, in the Dunedin longitudinal study, an inhibited behavioral style at age 3 was associated with depression diagnosis at age 21 (Caspi et al., 1996). Childhood inhibited temperament is also associated with later substance-use problems (Lahat et al., 2012; Williams et al., 2010). The link between inhibited temperament

and multiple psychiatric disorders suggests that childhood inhibited temperament may confer broader risk for psychopathology. However, the examination of inhibited temperament in patients with more severe and persistent disorders has been understudied. This is likely due to the challenges inherent in both community samples—where prevalence rates of severe disorders is low—and longitudinal studies, where even in high-risk populations, the small sample sizes restrict statistical power.

Several lines of evidence raise the possibility that inhibited temperament is associated with schizophrenia. Inhibited temperament and schizophrenia are both characterized by social dysfunction including shyness (Goldberg and Schmidt, 2001; Degnan et al., 2014) and social anxiety (Achim et al., 2011; Clauss and Blackford, 2012). Inhibited individuals and patients with schizophrenia also share a neural signature of hyperarousal, evidenced by hyper-reactivity to neutral images (Hall et al., 2008; Blackford et al., 2011), stressful situations (Kagan, Reznick and Snidman, 1987; Ryan et al., 2004; Walker et al., 2013), and cues signaling safety (Holt et al., 2012; Barker, Reeb-Sutherland and Fox, 2014). In addition, neuroimaging studies show a failure of neural habituation (Holt et al., 2005; Blackford et al., 2013; Williams et al., 2013), which may represent heightened threat detection or memory impairments (Avery et al., 2016). Given the challenges inherent in community samples and longitudinal studies, a logical first step is to measure childhood inhibited temperament in patients with schizophrenia. The Retrospective Self-Report of Inhibition (RSRI) is a well-validated measure that has been used to assess childhood inhibited temperament in two previous studies of patients with schizophrenia (Goldberg and Schmidt, 2001; Jetha, Goldberg and Schmidt, 2011). Goldberg and Schmidt (2001) measured childhood inhibited temperament in 23 outpatients with schizophrenia and 23 controls and found that childhood inhibited temperament scores were significantly higher in patients. However, childhood inhibited temperament was not correlated with positive or negative psychosis symptoms or quality of life. Jetha, Goldberg, and Schmidt (2011) later replicated higher inhibited temperament scores in a sample of 41 patients with schizophrenia and 41 controls, but did not examine correlations with symptoms. Thus, initial evidence suggests that childhood inhibited temperament may be a premorbid factor of schizophrenia.

Whether inhibited temperament is associated with heterogeneity in clinical symptoms or quality of life, and thus may identify a specific subgroup, remains unknown. Previous work suggests a subgroup of patients may have an affective pathway to psychosis that begins with heightened emotional reactivity prior to the onset of psychosis and has a more episodic course with better long-term outcomes (Myin-Germeys and van Os, 2007). The increased emotional reactivity is thought to reflect a genetic and/or environmental vulnerability for developing psychosis (Myin-Germeys and van Os, 2007). More recently, Dickinson and colleagues (2018) used the negative and distress subscales from the 5-factor model to examine the deficit and distress subtypes of schizophrenia. The distress subtype was characterized by high emotionality, increased anxiety and depressive symptoms, increased positive psychosis symptoms, higher cortisol levels, and more intact cognitive abilities. In contrast, the deficit subtype was characterized by diminished emotionality and enduring negative symptoms. Dickinson and colleagues proposed that these two subtypes reflect stable trait-like differences which may contribute to different pathways to psychosis.

Inhibited temperament may reflect the early vulnerability within the affective pathway to schizophrenia that could result in the distress subtype of schizophrenia.

Our goals in this study are to: replicate and extend the previous finding of higher childhood inhibited temperament in schizophrenia in a larger sample; and to determine whether individual differences in childhood inhibited temperament are associated with variability in anxiety, depression, psychosis symptoms, or quality of life in patients. We predict that patients will have higher levels of inhibited temperament, replicating findings from previous studies. We predict that inhibited temperament will account for significant variability in co-morbid anxiety and anxiety and depression symptoms in patients with schizophrenia. We hypothesize that patients with higher inhibited temperament associated with more co-morbid anxiety and higher levels of anxiety and depressive symptoms. Although previous studies of inhibited temperament in schizophrenia have used the PANSS three-factor model (Goldberg and Schmidt, 2001; Jetha et al., 2011), here we use the PANSS five-factor model based on recent findings supporting a distress subtype (Dickinson et al., 2018) and because it provides greater precision by splitting the general psychopathology subscale into three distinct measures of distress, excitement, and disorganization (Jerrell and Hrisko, 2013). For the PANSS factors, we hypothesize that inhibited temperament will predict variability in the Distress factor, based on its association with anxiety and depression, and in the Positive factor, as paranoia is proposed to be linked to anxiety through alterations in threat detection associated with anxiety (Tone and Davis, 2012) and shares a temperament vulnerability with social anxiety (Schutters et al., 2012).

2. Methods

2.1 Subjects

Participants consisted of 166 patients with schizophrenia spectrum disorders (80 schizophrenia, 33 schizoaffective disorder, and 53 schizophreniform disorder) and 180 healthy controls. The Vanderbilt University Institutional Review Board approved the study and participants provided written consent. Patients were recruited from the inpatient units and outpatient clinics of Vanderbilt Psychiatric Hospital into a registered repository from 2008 through 2017 (clinicaltrials.gov;). Healthy controls were recruited from advertisements in the community. A Structured Clinical Interview of the DSM-IV-TR (SCID) (First et al., 2002) was conducted for all participants by trained research staff. Participants were considered for study if they were between 14–65 years old, had premorbid IQ >70, no history of traumatic brain injury, did not suffer from a chronic medical illness (e.g. HIV, cancer) or a central nervous system disorder, and did not meet criteria for current substance abuse/dependence. Healthy control participants were excluded if they had a history of psychiatric disorders. For patients, the SCID was used to confirm diagnosis of schizophrenia spectrum and anxiety disorders. In healthy control participants, the SCID was used to rule out past or current psychiatric illness including substance abuse/dependence. Patients and healthy controls were compensated for participating the study.

2.2 Procedures

Childhood inhibited temperament was assessed with the Retrospective Self-Report of Inhibition (RSRI; Reznick *et al.* 1992). The RSRI is a retrospective self-report questionnaire assessing inhibited behaviors during childhood (grades 1–6) across a variety of contexts. For example, questions on the RSRI include “Did it upset you to be called up to the blackboard” and “Did you enjoy meeting new children your age?” RSRI has 30 questions and uses a Likert scale (1 = uninhibited, 5 = inhibited); the RSRI score is the average of all of the items. The RSRI has excellent reliability (Cronbach’s $\alpha = .79$) and construct validity, indicated by strong agreement between self-reports by individuals and reports from their parents and by correlations with concurrent measures (Reznick *et al.*, 1992).

Anxiety and depression symptoms were measured using the Mood and Anxiety Symptom Questionnaire (MASQ; Watson *et al.*, 1995). The MASQ is a 90-item self-report measure of anxiety and depression symptoms that uses a 1–5 Likert scale (1 = not at all, 5 = extremely). The MASQ is based on the tripartite model of anxiety and depression which separates symptoms into three clusters: general distress/negative affect (shared by anxiety and depression), physiological hyperarousal (specific to anxiety), and positive affect (specific to depression). Negative affect is measured by three subscales (general distress-anxiety, general distress-depression, and general distress), anxiety is measured by the Anxious Arousal subscale and depression is measured by the Anhedonic Depression subscale.

Quality of life was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-Q-SF), a self-report measure of quality and satisfaction in the past week (Becchi *et al.*, 2004). For example, the Q-LES-Q-SF asks “Taking everything into consideration, during the past week how satisfied have you been with your social relationships. The Q-LES-Q-SF has 16 Likert scale items (1 = very poor, 5 = very good) and the quality of life score is the total across all items (range 16 – 80). The quality of life measure was available for a subset of 59 patients.

The Positive and Negative Syndrome Scale (PANSS; Kay, Fiszbein and Opler, 1987) was administered by a clinician to assess the severity of symptoms. A five-factor model most commonly characterizes the PANSS items (Wallwork *et al.*, 2012) and composite scores for Negative, Positive, Disorganized, Excitement and Distress symptom factors were computed (van der Gaag *et al.*, 2006).

2.3 Data analyses

To determine whether inhibited temperament differed between patients with schizophrenia versus healthy controls, an ANOVA was performed on inhibited temperament score with diagnosis (patients/controls) as the between-subjects factor. To determine whether levels of inhibited temperament differed across the three schizophrenia spectrum diagnoses, an ANOVA was performed on inhibited temperament score with diagnostic group (schizophrenia/schizoaffective/schizophreniform).

To determine whether individual differences in inhibited temperament explained heterogeneity in patients with schizophrenia, a series of analyses were performed within the patient group. First, a logistic regression was performed to determine if inhibited

temperament predicts anxiety diagnosis (yes/no). Next, regression analyses were conducted to test for associations between the inhibited temperament score and each of the outcome measures (MASQ subscales, PANSS factors, and quality of life). Age and age of onset were covariates in all regression analyses. The standardized parameter estimates, t-values, effect sizes, and p-values will be reported for each outcome variable. All analyses were conducted using SAS software (Version 9.4, SAS Institute Inc., Cary, NC), $\alpha < 0.05$.

3. Results

3.1 Comparison of Patients and Controls

Demographic and symptoms measures for patients and controls are shown in Table 1. Patients and controls were similar in all of the demographic characteristics, except for education; patients had less education than controls, $F(1, 315) = 54.96$, $p < .0001$. Compared to controls, patients had significantly higher inhibited temperament scores ($F(1, 344) = 82.26$, $p < .0001$). As illustrated in Figure 1, the higher scores reflected a greater variability in scores (Levene's test, $F(1, 344) = 18.17$, $p < .0001$), especially towards the more inhibited end of the distribution and not merely a general shift towards higher scores. Inhibited temperament did not differ across the three schizophrenia spectrum disorder diagnoses (schizophrenia/ schizoaffective/ schizophreniform; $F(2, 163) = 2.44$, $p = .09$), therefore, all patients were combined into one patient group for the subsequent analyses. On the symptom measures, patients had significantly higher scores on all of the MASQ measures of negative affect/general distress, anxiety, and depression, as well as lower quality of life (all $p < .05$, Table 1).

3.2 Inhibited Temperament and Outcomes in Patients

In patients, inhibited temperament was significantly associated with having a co-morbid anxiety disorder ($\chi^2 = 19.22$, $p < .0001$) with a 4.64 increase in odds for each unit increase in temperament score (e.g., 3 to 4 on the 1 – 5 scale). In the regression analyses controlling for age and age of onset, inhibited temperament was significantly associated with higher scores on the MASQ anxious arousal subscale and MASQ anhedonic depression subscale. Inhibited temperament also predicted significant variance in the MASQ negative affect subscales: higher inhibited temperament was associated with more general distress-anxiety, general distress-depression, general distress-mixed. The standardized parameter estimates, effect sizes, and p-values are provided in Table 2 and scatterplots illustrating the relationships are provided in Figure 2.

Within patients, inhibited temperament was associated with two of the PANSS factors. Patients with higher inhibited temperament scores had significantly higher scores on the PANSS Distress factor. Higher inhibited temperament was also associated with lower scores on the PANSS Excitement factor. Inhibited temperament did not predict variability in PANSS Disorganization, PANSS Positive, or PANSS Negative factors. The standardized parameter estimates, effect sizes, and p-values are provided in Table 2 and scatterplots illustrating the relationships are provided in Figure 2.

The quality of life analysis was conducted with a subset of patients that completed the Q-LES-Q-SF. Higher inhibited temperament scores predicted significantly lower quality of life. The standardized parameter estimate, effect size, and p-value is provided in Table 2 and the scatterplot is provided in Figure 2.

3.3 Unique Contributions of Inhibited Temperament Controlling for Anxiety Disorders

To address the possibility that inhibited temperament is capturing variability more parsimoniously attributable to co-morbid anxiety, regression analyses were repeated covarying for anxiety (yes/no). After controlling for anxiety disorders, inhibited temperament continued to explain a significant portion of variability in all of the anxiety and depression symptom measures (MASQ subscales, all $p < .0001$, PANSS Excitement factor ($p = .02$), PANSS Distress factor ($p = .002$), and quality of life ($p = .006$)).

4. Discussion

Inhibited temperament has been implicated in anxiety disorders, depression, and substance use; however, little is known about the role of inhibited temperament in severe and persistent mental illnesses such as schizophrenia. The first goal of this study was to test the hypothesis that patients with schizophrenia would have higher childhood inhibited temperament. The second goal of the study was to determine whether inhibited temperament was associated with a distinct set of correlates in patients with schizophrenia, providing initial evidence for subgroups. There were two major findings. First, patients with schizophrenia were significantly more inhibited than control participants, providing evidence that inhibited temperament is prominent in schizophrenia, similar to findings in other psychiatric disorders. Second, inhibited temperament was significantly correlated with mood and anxiety symptoms and quality of life, but was not associated with psychosis symptoms. Patients with the highest inhibited temperament scores were characterized by high anxiety and depression, high distress, low excitement, and low quality of life.

Patients had higher inhibited temperament scores than healthy controls, which reflected both greater variability in scores and a shift in the distribution towards more inhibited temperament. The finding that patients with schizophrenia are, on average, more inhibited than controls replicates two smaller studies (Goldberg and Schmidt, 2001; Jetha, Goldberg and Schmidt, 2011) and together, these studies provide compelling evidence that inhibited temperament is prominent in schizophrenia. This finding adds to a growing literature showing that inhibited temperament is associated with psychiatric disorders and provides an important extension from less severe disorders, like anxiety and depression, to severe and persistent mental illnesses, like schizophrenia. Inhibited temperament may reflect a vulnerability within patients with schizophrenia consistent with stress vulnerability models of schizophrenia (Davis et al., 2016; Zubin and Spring, 1977), a distress subtype (Dickinson et al., 2018), or an affective pathway to psychosis (Dickinson et al., 2018; Myin-Germeys and van Os, 2007). More specifically, we propose that inhibited temperament may reflect an early emerging, biologically-based vulnerability for schizophrenia with increased emotional reactivity and increased stress sensitivity that leads to a distress subtype of schizophrenia with heightened anxiety and mood symptoms. The higher levels of inhibited temperament in

schizophrenia raise two questions for future research. First, “Does inhibited temperament confer increased risk for developing schizophrenia?” A meta-analytic study of prospective longitudinal studies estimated a 7-fold increase in odds for developing social anxiety disorder in inhibited children (Clauss and Blackford, 2012). Given the low prevalence of schizophrenia in the population, very large longitudinal datasets with early measures of temperament are needed to examine this question in schizophrenia. Second, “Is inhibited temperament transdiagnostic?” Future studies examining inhibited temperament across multiple disorders will be needed to determine whether inhibited temperament is more prevalent across all psychiatric disorders or only in specific disorders, for example those with high rates of anxiety.

Inhibited temperament explained significant heterogeneity across measures of negative affect, anxiety, and depression. Specifically, inhibited temperament was associated with higher scores on the MASQ negative affect measures, MASQ anxiety scale, MASQ depression scale, and PANSS Distress factor. Anxiety and depression symptoms are common in schizophrenia and are observed across all phases of the disease progression including in ultra-high risk individuals (Fusar-Poli et al., 2014), during the first episode of psychosis (Sutliff, Roy and Achim, 2015), and in chronic schizophrenia (Achim et al., 2011; Lim et al., 2015). In addition to heightened levels of anxiety in the current study, inhibited temperament was associated with a significant increase in odds of having a co-morbid anxiety disorder. The high rates of comorbid anxiety disorders in patients has gained recent attention following a meta-analytic study that reported that 38% of patients with schizophrenia have a co-morbid anxiety disorder (Achim et al., 2011). The pattern of symptoms associated with inhibited temperament is consistent with descriptions of an ‘affective pathway’ to psychosis (Myin-Germeys and van Os, 2007) or a distress subtype (Dickinson et al., 2018). Heightened anxiety and depression symptoms in schizophrenia have multiple important implications for patient outcomes. Patients with co-morbid anxiety and schizophrenia have higher rate of suicide attempts, increased substance abuse, worse social adjustment, and lower overall quality of life (Pallanti, Quercioli and Hollander, 2004). Depression in patients with schizophrenia is also associated with worse long-term functional outcomes (Conley et al., 2007). Despite the prevalence and importance of anxiety and depression in schizophrenia, these disorders and symptoms remain underrecognized and understudied. It will be critical for future studies of schizophrenia to include comprehensive measures of anxiety and depression in order to further our understanding of the role of anxiety and depression in functional impairment, treatment response, and long-term outcomes.

Higher inhibited temperament was associated with decreased satisfaction with quality of life. Our findings are consistent with several previous studies. One study found that in patients with schizophrenia, higher shyness was correlated with both lower quality of life and impaired interpersonal functioning (Jetha, Goldberg and Schmidt, 2011). In addition, patients with comorbid schizophrenia and social anxiety disorder have lower quality of life compared to patients with schizophrenia without comorbid social anxiety (Pallanti, Quercioli and Hollander, 2004). Although inferences from correlations are inherently limited, inhibited temperament typically emerges early in life and has been shown to predict later social withdrawal (Pérez-Edgar et al., 2011; Walker et al., 2014) and social anxiety

(Clauss and Blackford, 2012). Thus, one possibility is that inhibited temperament leads to impaired social functioning and social anxiety, which in turn leads to lower satisfaction, through either lack of social support and connectedness or potentially through negative cognitive biases impacting perception of quality of life. In a longitudinal study of patients, baseline low quality of life and emotional distress predicted poor quality of life 10-years later (Ritsner, Lisker and Grinshpoon, 2014). Interventions targeting inhibited temperament have the potential to both reduce anxiety and depression, and improve quality of life, both of which may improve long-term outcomes.

Contrary to our hypothesis, inhibited temperament was not associated with positive symptoms. Our prediction was based on the role of attentional bias to threat and anxiety in paranoia (Tone and Davis, 2012) and based on a large epidemiological study where inhibited temperament was elevated in individuals who endorsed paranoia symptoms (Schutters et al., 2012). Of note, the one previous study that investigated inhibited temperament and PANSS scores also failed to find an association with the PANSS Positive, Negative, or General factors (Goldberg and Schmidt, 2001). Findings in studies of similar temperament and personality factors (like negative affect, neuroticism, and harm avoidance) have been mixed (for a review see Horan et al., 2008). One possibility is that the contribution of inhibited temperament is specific to affective symptoms. Another possibility is that alternative methods of characterizing symptoms that use different time scales (e.g. repeated measures over time or experience sampling methods) or different resolutions (e.g., just paranoia symptoms, or specific delusion or hallucination content) may provide a novel perspective on the relationship between inhibited temperament and positive symptoms.

The findings from the current study should be considered in the context of potential limitations. First, inhibited temperament was assessed using a self-report, retrospective measure. Self-report measures assume reliable reporting, which may be a concern in patient populations, especially populations with cognitive impairments. Patients in this study had lower levels of education than the controls, although on average they had completed one year of college. In addition, self-report has been shown to be consistent with clinician reports in patients with schizophrenia (Becchi et al., 2004) and previous studies have used the specific RSRI measure in patients with schizophrenia (Goldberg and Schmidt, 2001; Jetha, Goldberg and Schmidt, 2011). Another study limitation is that the data are cross-sectional. While data from other studies show a convergence between findings from cross-sectional (Gladstone et al., 2005) and longitudinal studies (Caspi et al., 1996; Chronis-Tuscano et al., 2009; Clauss and Blackford, 2012; Essex et al., 2013) of inhibited temperament and psychopathology, longitudinal studies are critical for establishing a temporal link between childhood inhibited temperament and later schizophrenia.

In summary, we show that inhibited temperament is prominent in schizophrenia and accounts for significant heterogeneity in an anxiety and depression phenotype. Thus, differences in temperament, in addition to clinical and cognitive factors, should be included in attempts to parse heterogeneity in schizophrenia. Inhibited temperament emerges early in development and is relatively stable over time; therefore, it has potential to be a premorbid risk factor that could be targeted for preventative interventions including social skill training (Jetha et al., 2007)]. In addition, patients with schizophrenia with inhibited temperament

have elevated anxiety and depression symptoms and may potentially benefit from treatments focused on those symptoms such as adjunctive anxiolytic or antidepressant medications (Stroup et al., 2019).

Acknowledgments

Support for this project was provided by the Charlotte and Donald Test Fund, the Jack Martin MD Research Professorship in Psychopharmacology (JUB), NIMH grant R01-MH70560 (SH), NIMH grant R01-MH102266 (NDW), the Vanderbilt Psychiatric Genotype/Phenotype Project, and the Vanderbilt Institute for Clinical and Translational Research (through grant 1-UL1-TR000445 from the National Center for Research Resources/NIH). Dr. Blackford's time was partially supported by a Merit Award (CX001226) from the US Department of Veterans Affairs.

References

- Achim AM, Maziade M, Raymond E, Olivier D, Mérette C, Roy M-A, Me C, 2011 How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. *Schizophr. Bull* 37, 811–21. 10.1093/schbul/sbp148 [PubMed: 19959704]
- Avery SN, Vanderklok RM, Heckers S, Blackford JU, 2016 Impaired face recognition is associated with social inhibition. *Psychiatry Res* 10.1016/j.str.2014.12.012
- Barker TV, Reeb-Sutherland BC, Fox NA, 2014 Individual differences in fear potentiated startle in behaviorally inhibited children. *Dev. Psychobiol* 56, 133–141. 10.1002/dev.21096 [PubMed: 23341151]
- Becchi A, Rucci P, Placentino A, Neri G, de Girolamo G, 2004 Quality of life in patients with schizophrenia – comparison of self-report and proxy assessments. *Soc. Psychiatry Psychiatr. Epidemiol* 39, 397–401. 10.1007/s00127-004-0761-5 [PubMed: 15133597]
- Beesdo K, Bittner A, Pine DS, Stein MB, Hofler M, Lieb R, Wittchen H-U, 2007 Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. *Arch. Gen. Psychiatry* 64, 903–912. [PubMed: 17679635]
- Biederman J, Hirshfeld-Becker DR, Rosenbaum JF, Herot C, Friedman D, Snidman N, Kagan J, Faraone SV, 2001 Further evidence of association between behavioral inhibition and social anxiety in children. *Am. J. Psychiatry* 158, 1673–1679. [PubMed: 11579001]
- Biederman J, Rosenbaum JF, Bolducmurphy EA, Faraone SV, Chaloff J, Hirshfeld DR, Kagan J, 1993 A 3-Year follow-up of children with and without behavioral-inhibition. *J. Am. Acad. Child Adolesc. Psychiatry* 32, 814–821. [PubMed: 8340303]
- Blackford JU, Allen AH, Cowan RL, Avery SN, 2013 Amygdala and hippocampus fail to habituate to faces in individuals with an inhibited temperament. *Soc. Cogn. Affect. Neurosci* 8, 143–150. 10.1093/scan/nsr078 [PubMed: 22260816]
- Blackford JU, Avery SN, Cowan RL, Shelton RC, Zald DH, 2011 Sustained amygdala response to both novel and newly familiar faces characterizes inhibited temperament. *Soc. Cogn. Affect. Neurosci* 6, 621–629. 10.1093/scan/nsq073 [PubMed: 20660534]
- Calkins SD, Fox NA, Marshall TR, 1996 Behavioral and physiological antecedents of inhibited and uninhibited behavior. *Child Dev* 67, 523–540. [PubMed: 8625726]
- Carpenter WT, Kirpatrick B, 1988 The heterogeneity of the long-term course of schizophrenia. *Schizophr. Bull* 14, 645–652. [PubMed: 3064288]
- Caspi A, Moffitt TE, Newman DL, Silva PA, 1996 Behavioral observations at age 3 years predict adult psychiatric disorders. Longitudinal evidence from a birth cohort. *Arch. Gen. Psychiatry* 53, 1033–1039. [PubMed: 8911226]
- Chronis-Tuscano A, Degnan KA, Pine DS, Pérez-Edgar K, Henderson HA, Diaz Y, Raggi VL, Fox NA, 2009 Stable early maternal report of behavioral inhibition predicts lifetime social anxiety disorder in adolescence. *J. Am. Acad. Child Adolesc. Psychiatry* 48, 928–935. [PubMed: 19625982]

- Clauss JA, Blackford JU, 2012 Behavioral inhibition and risk for developing social anxiety disorder: a meta-analytic study. *J. Am. Acad. Child Adolesc. Psychiatry* 51, 1066–1075.e1. 10.1016/j.jaac.2012.08.002 [PubMed: 23021481]
- Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ, 2007 The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. *Schizophr. Res* 90, 186–197. 10.1016/j.schres.2006.09.027 [PubMed: 17110087]
- Davis J, Eyre H, Jacka FN, Dodd S, Dean O, Debnath M, Mcgrath J, Maes M, Amminger P, Pantelis C, Berk M, Health B, Block M, Melbourne R, Behavior H, States U, Health OY, Centre N, Health M, Myer K, 2016 A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. *Neurosci. Biobehav. Rev* 65, 185–194. 10.1016/j.neubiorev.2016.03.017.A [PubMed: 27073049]
- Degnan KA, Almas AN, Henderson HA, Hane AA, Walker OL, Fox NA, 2014 Longitudinal trajectories of social reticence with unfamiliar peers across early childhood. *Dev. Psychol* 50, 2311–2323. 10.1037/a0037751 [PubMed: 25181648]
- Dickinson D, Pratt DN, Giangrande EJ, Grunnagle M, Orel J, Weinberger DR, Callicott JH, Berman KF, 2018 Attacking heterogeneity in schizophrenia by deriving clinical subgroups from widely available symptom data. *Schizophr. Bull* 44, 101–113. 10.1093/schbul/sbx039 [PubMed: 28369611]
- Dilalla LF, Kagan J, Reznick JS, 1994 Genetic etiology of behavioral inhibition among 2-year-old children. *Infant Behav. Dev* 17, 405–412. 10.1016/0163-6383(94)90032-9
- Eley TC, Bolton D, O'Connor TG, Perrin S, Smith P, Plomin R, 2003 A twin study of anxiety-related behaviours in pre-school children. *J. Child Psychol. Psychiatry Allied Discip* 44, 945–60.
- Essex MJ, Boyce WT, Hertzman C, Lam LL, Armstrong JM, 2013 Epigenetic vestiges of early developmental adversity: Childhood stress exposure and DNA methylation in adolescence. *Child Dev* 84, 58–75. 10.1111/j.1467-8624.2011.01641.x.Epigenetic [PubMed: 21883162]
- Essex MJ, Klein MH, Slattery MJ, Goldsmith HHH, Kalin NH, 2010 Early risk factors and developmental pathways to chronic high inhibition and social anxiety disorder in adolescence. *Am. J. Psychiatry* 167, 40–46. 10.1176/appi.ajp.2009.07010051 [PubMed: 19917594]
- First MB, Spitzer RL, Gibbon M, Williams JBW, 2002 Structured Clinical Interview For DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P) Biometrics Research, New York State Psychiatric Institute, New York.
- Fuller R, Nopoulos P, Arndt S, O'Leary D, Ho BC, Andreasen NC, 2002 Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance. *Am. J. Psychiatry* 159, 1183–1189. 10.1176/appi.ajp.159.7.1183 [PubMed: 12091197]
- Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK, 2014 Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: Impact on psychopathology and transition to psychosis. *Schizophr. Bull* 40, 120–131. 10.1093/schbul/sbs136 [PubMed: 23180756]
- Gladstone GL, Parker GB, 2006 Is behavioral inhibition a risk factor for depression? *J. Affect. Disord* 95, 85–94. 10.1016/j.jad.2006.04.015 [PubMed: 16808978]
- Gladstone GL, Parker GB, Mitchell PB, Wilhelm KA, Malhi GS, 2005 Relationship between self-reported childhood behavioral inhibition and lifetime anxiety disorders in a clinical sample. *Depress. Anxiety* 22, 103–113. [PubMed: 16149043]
- Goldberg JO, Schmidt LA, 2001 Shyness, sociability, and social dysfunction in schizophrenia. *Schizophr. Res* 48, 343–349. [PubMed: 11295386]
- Hall J, Whalley HC, McKirdy JW, Romaniuk L, McGonigle D, McIntosh AM, Baig BJ, Gountouna V-E, Job DE, Donaldson DI, Sprengelmeyer R, Young AW, Johnstone EC, Lawrie SM, 2008 Overactivation of fear systems to neutral faces in schizophrenia. *Biol. Psychiatry* 64, 70–73. 10.1016/j.biopsych.2007.12.014 [PubMed: 18295746]
- Hirshfeld-Becker DR, Masek B, Henin A, Blakely LR, Pollock-Wurman RA, McQuade J, DePetrillo L, Briesch J, Ollendick TH, Rosenbaum JF, Biederman J, 2010 Cognitive behavioral therapy for 4- to 7-year-old children with anxiety disorders: a randomized clinical trial. *J. Consult. Clin. Psychol* 78, 498–510. 10.1037/a0019055 [PubMed: 20658807]

- Hirshfeld DR, Rosenbaum JF, Biederman J, Bolduc EA, Faraone SV, Snidman N, Reznick JS, Kagan J, 1992 Stable behavioral-inhibition and its association with anxiety disorder. *J. Am. Acad. Child Adolesc. Psychiatry* 31, 103–111. [PubMed: 1537760]
- Holt DJ, Coombs G, Zeidan MA, Goff DC, Milad MR, 2012 Failure of neural responses to safety cues in schizophrenia. *Arch. Gen. Psychiatry* 69, 893–903. 10.1001/archgenpsychiatry.2011.2310 [PubMed: 22945619]
- Holt DJ, Weiss AP, Rauch SL, Wright CI, Zalesak M, Goff DC, Ditman T, Welsh RC, Heckers S, 2005 Sustained activation of the hippocampus in response to fearful faces in schizophrenia. *Biol. Psychiatry* 57, 1011–1019. 10.1016/j.biopsych.2005.01.033 [PubMed: 15860342]
- Horan WP, Blanchard JJ, Clark LA, Green MF, 2008 Affective traits in schizophrenia and schizotypy. *Schizophr. Bull* 34, 856–874. 10.1093/schbul/sbn083 [PubMed: 18667393]
- Jerrell JM, Hrisco S, 2013 Utility of Two PANSS 5-Factor Models for Assessing Psychosocial Outcomes in Clinical Programs for Persons with Schizophrenia. *Schizophr. Res. Treatment* 2013, 1–9. 10.1155/2013/705631
- Jetha MK, Goldberg JO, Schmidt LA, 2011 Temperament and its relation to social functioning in schizophrenia. *Int. J. Soc. Psychiatry* 59, 254–263. 10.1177/0020764011433639
- Jetha MK, Schmidt LA, Goldberg JO, 2007 Stability of shyness, sociability, and social dysfunction in schizophrenia: A preliminary investigation of the influence of social skills training in a community-based stable outpatient sample. *Eur. J. Psychiatry* 21, 189–198. 10.4321/s0213-61632007000300003
- Kagan J, Reznick JS, Clarke C, Snidman N, Garcia Coll C, 1984 Behavioral inhibition to the unfamiliar. *Child Dev* 55, 2212–2225.
- Kagan J, Reznick JS, Snidman N, 1987 The physiology and psychology of behavioral-inhibition in children. *Child Dev* 58, 1459–1473. [PubMed: 3691195]
- Kagan J, Snidman N, Arcus D, 1998 Childhood derivatives of high and low reactivity in infancy. *Child Dev* 69, 1483–1493. 10.1111/j.1467-8624.1998.tb06171.x [PubMed: 9914634]
- Kay SR, Fiszbein A, Oplet LA, 1987 The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. *Schizophr. Bull* 13, 261–76. [PubMed: 3616518]
- Lahat A, Pérez-Edgar K, Degnan KA, Guyer AE, Lejuez CW, Ernst M, Pine DS, Fox NA, 2012 Early childhood temperament predicts substance use in young adults. *Transl. Psychiatry* 2, e157 10.1038/tp.2012.87 [PubMed: 22948382]
- Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RSE, Lee J, 2015 Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS). *Schizophr. Res* 164, 8–14. 10.1016/j.schres.2015.03.007 [PubMed: 25818728]
- Lönnqvist JE, Verkasalo M, Haukka J, Nyman K, Tiihonen J, Laaksonen I, Leskinen J, Lönnqvist J, Henriksson M, 2009 Premorbid personality factors in schizophrenia and bipolar disorder: results from a large cohort study of male conscripts. *J. Abnorm. Psychol* 118, 418–423. 10.1037/a0015127 [PubMed: 19413416]
- Mollon J, Reichenberg A, 2018 Cognitive development prior to onset of psychosis. *Psychol. Med* 48, 392–403. [PubMed: 28735586]
- Murray RM, Lewis SW, 1987 Is schizophrenia a neurodevelopmental disorder? *BMJ* 295, 681. [PubMed: 3117295]
- Myin-Germeys I, van Os J, 2007 Stress-reactivity in psychosis: Evidence for an affective pathway to psychosis. *Clin. Psychol. Rev* 27, 409–424. 10.1016/j.cpr.2006.09.005 [PubMed: 17222489]
- Neal JA, Edelmann RJ, Glachan M, 2002 Behavioural inhibition and symptoms of anxiety and depression: Is there a specific relationship with social phobia? *Br. J. Clin. Psychol* 41, 361–374. [PubMed: 12437791]
- Pallanti S, Quercioli L, Hollander E, 2004 Social anxiety in outpatients with schizophrenia: A relevant cause of disability. *Am. J. Psychiatry* 161, 53–58. 10.1176/appi.ajp.161.1.53 [PubMed: 14702250]
- Pérez-Edgar K, Reeb-Sutherland BC, McDermott JM, White LK, Henderson H.a, Degnan K. a, Hane AA, Pine DS, Fox NA, Pérez-Edgar K, 2011 Attention biases to threat link behavioral inhibition to social withdrawal over time in very young children. *J. Abnorm. Child Psychol* 39, 1–11. 10.1007/s10802-011-9495-5 [PubMed: 20644990]

- Reznick JS, Hegeman IM, Kaufman ER, Woods SW, Jacobs M, 1992 Retrospective and concurrent self-report of behavioral-inhibition and their relation to adult mental-health. *Dev. Psychopathol*
- Ritsner MS, Lisker A, Grinshpoon A, 2014 Predicting 10-year quality-of-life outcomes of patients with schizophrenia and schizoaffective disorders. *Psychiatry Clin. Neurosci* 68, 308–317. 10.1111/pcn.12135 [PubMed: 24405469]
- Robinson JAL, Kagan J, Reznick JS, Corley R, Kagan J, Corley R, 1992 The heritability of inhibited and uninhibited behavior: a twin study. *Dev. Psychol* 28, 1030–1037. 10.1037/0012-1649.28.6.1030
- Ryan MCM, Sharifi N, Condren R, Thakore JH, 2004 Evidence of basal pituitary-adrenal overactivity in first episode, drug naïve patients with schizophrenia. *Psychoneuroendocrinology* 29, 1065–1070. 10.1016/j.psyneuen.2003.08.011 [PubMed: 15219658]
- Schutters SIJ, Dominguez MDG, Knappe S, Lieb R, Van Os J, Schruers KRJ, Wittchen HU, 2012 The association between social phobia, social anxiety cognitions and paranoid symptoms. *Acta Psychiatr. Scand* 125, 213–227. 10.1111/j.1600-0447.2011.01787.x [PubMed: 22077136]
- Schwartz CE, Snidman N, Kagan J, 1999 Adolescent social anxiety as an outcome of inhibited temperament in childhood. *J. Am. Acad. Child Adolesc. Psychiatry* 38, 1008–1015. [PubMed: 10434493]
- Smith AK, Rhee SH, Corley RP, Friedman NP, Hewitt JK, Robinson JL, 2012 The magnitude of genetic and environmental influences on parental and observational measures of behavioral inhibition and shyness in toddlerhood. *Behav. Genet* 42, 764–777. 10.1007/s10519-012-9551-0 [PubMed: 22806186]
- Stroup TS, Gerhard T, Crystal S, Huang C, Tan Z, Wall MM, Mathai C, Olfson M, 2019 Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia. *JAMA Psychiatry* 10032, 1–8. 10.1001/jamapsychiatry.2018.4489
- Sutliff S, Roy M-A, Achim AM, 2015 Social anxiety disorder in recent onset schizophrenia spectrum disorders: The relation with symptomatology, anxiety, and social rank. *Psychiatry Res* 227, 39–45. 10.1016/j.psychres.2015.02.017 [PubMed: 25818255]
- Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M, Van Os J, Carpenter W, 2013 Definition and description of schizophrenia in the DSM-5. *Schizophr. Res* 150, 3–10. 10.1016/j.schres.2013.05.028 [PubMed: 23800613]
- Tarbox SI, Pogue-Geile MF, 2008 Development of social functioning in preschizophrenia children and adolescents: a systematic review. *Psychol. Bull* 134, 561–583. 10.1037/0033-2909.34.4.561 [PubMed: 18605820]
- Tone EB, Davis JS, 2012 Paranoid thinking, suspicion, and risk for aggression: A neurodevelopmental perspective. *Dev. Psychopathol* 24, 1031–1046. 10.1017/S0954579412000521 [PubMed: 22781870]
- Trotta A, Murray RM, MacCabe JH, 2015 Do premorbid and post-onset cognitive functioning differ between schizophrenia and bipolar disorder? A systematic review and meta-analysis. *Psychol. Med* 45, 381–394. [PubMed: 25065268]
- Tsuji T, Kline E, Sorensen HJ, Mortensen EL, Michelsen NM, Ekstrom M, Mednick S, Schiffman J, 2013 Premorbid teacher-rated social functioning predicts adult schizophrenia-spectrum disorder: A high-risk prospective investigation. *Schizophr. Res* 151, 270–273. 10.1016/j.schres.2013.10.022 [PubMed: 24210529]
- van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, van Harten PN, Valmaggia L, de Hert M, Cuijpers A, Wiersma D, 2006 The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model. *Schizophr. Res* 85, 280–287. 10.1016/j.schres.2006.03.021 [PubMed: 16730429]
- Van Os J, Jones PB, 2001 Neuroticism as a risk factor for schizophrenia. *Psychol. Med* 31, 1129–1134. [PubMed: 11513380]
- Walker E, Lewine R, 1990 Prediction of adult-onset schizophrenia from childhood home movies of the patients. *Am. J. Psychiatry* 147, 1052–1056. [PubMed: 2375440]
- Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA, Heinssen R, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, McGlashan TH, Woods SW, 2013 Cortisol levels and risk for psychosis: Initial findings from the North American Prodrome

- Longitudinal Study. *Biol. Psychiatry* 74, 410–417. 10.1016/j.biopsych.2013.02.016 [PubMed: 23562006]
- Walker OL, Henderson HA, Degnan KA, Penela EC, Fox NA, 2014 Associations between behavioral inhibition and children's social problem-solving behavior during social exclusion. *Soc. Dev* 23, 487–501. 10.1111/sode.12053 [PubMed: 25360063]
- Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D, 2012 Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. *Schizophr. Res* 137, 246–250. 10.1016/j.schres.2012.01.031 [PubMed: 22356801]
- Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA, 1995 Testing a tripartite model: II. Exploring the symptom structure of anxiety and depression in student, adult, and patient samples. *J. Abnorm. Psychol* 104, 3–14. 10.1037/0021-843X.104.1.3 [PubMed: 7897050]
- Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR, 2000 Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. *Arch. Gen. Psychiatry* 57, 907–913. 10.1001/archpsyc.57.9.907 [PubMed: 10986554]
- Williams LE, Blackford JU, Luksik A, Gauthier I, Heckers S, 2013 Reduced habituation in patients with schizophrenia. *Schizophr. Res* 151, 124–132. 10.1016/j.schres.2013.10.017 [PubMed: 24200419]
- Williams LR, Fox NA, Lejuez CW, Reynolds EK, Henderson HA, Pérez-Edgar K, Steinberg L, Pine DS, 2010 Early temperament, propensity for risk-taking and adolescent substance-related problems: A prospective multi-method investigation. *Addict. Behav* 35, 1148–1151. 10.1016/j.addbeh.2010.07.005 [PubMed: 20813463]
- Woodward ND, Heckers S, 2015 Brain structure in neuropsychologically defined subgroups of schizophrenia and psychotic bipolar disorder. *Schizophr. Bull* 41, 1349–1359. 10.1093/schbul/sbv048 [PubMed: 25904725]
- Zubin J, Spring B, 1977 Vulnerability: A new view of schizophrenia. *J. Abnorm. Psychol* 10.1037/0021-843X.86.2.103

Figure 1: Distribution of inhibited temperament scores in the healthy control and schizophrenia groups. The histograms by group illustrate that the higher mean inhibited temperament scores in patients reflect a greater variability in scores with a substantially greater number of individuals scoring in the higher range of the scale.

Figure 2:

Scatterplots illustrating the relationship between inhibited temperament and outcome measures. In patients with schizophrenia, inhibited temperament was positively correlated with measures of anxious arousal, anhedonic depression, general distress-mixed, general distress-anxiety, general distress-depression, and PANSS Distress. Inhibited temperament was negatively correlated with quality of life and PANSS Excited but was not correlated with PANSS Positive or PANSS Negative.

Table 1.**Participant Characteristics by Diagnosis Group**

	Schizophrenia (N = 166)	Controls (N = 180)	p-value
% Male	67%	58%	.08
% White	66%	71%	.28
Age (SD)	29.86 (11.75)	29.42 (10.82)	.58
Education (SD)	13.24 (2.36)	15.19 (2.33)	<0.001
Parental Education (SD)	14.35 (2.97)	14.65 (2.39)	.34
Inhibited Temperament (SD)	2.37 (0.59)	1.89 (0.37)	<0.001
% Anxiety Disorder	32%	--	--
MASQ			
Anxious Arousal (SD)	1.75 (0.66)	1.14 (0.21)	<0.001
Anhedonic Depression (SD)	2.91 (0.64)	2.18 (0.47)	<0.001
General Distress-Anxiety (SD)	1.99 (0.74)	1.36 (0.36)	<0.001
General Distress-Depression (SD)	2.34 (0.97)	1.45 (0.47)	<0.001
General Distress-Mixed (SD)	2.40 (0.85)	1.53 (0.46)	<0.001
PANSS			
Negative (SD)	2.29 (1.24)	--	--
Positive (SD)	2.96 (1.32)	--	--
Excitement (SD)	1.50 (0.65)	--	--
Disorganization (SD)	2.48 (1.17)	--	--
Distress (SD)	2.27 (1.02)	--	--
Quality of Life	49.24 (8.95)	58.44 (5.80)	.01

Table 2.

Anxiety Symptoms, Psychosis Symptoms, And Quality of Life by Temperament

Outcome Variable	Standardized Parameter Estimate	T value	Effect size (η^2)	P-Value
MASQ				
Anxious Arousal	0.43	6.05	0.17	<.0001
Anhedonic Depression	0.45	6.31	0.19	<.0001
General Distress-Anxiety	0.45	6.30	0.19	<.0001
General Distress-Depression	0.53	7.73	0.26	<.0001
General Distress-Mixed	0.56	8.43	0.29	<.0001
PANSS				
Negative	-0.06	0.44	0.00	.50
Positive	0.04	-0.68	0.00	.66
Excitement	-0.22	-2.84	0.05	.005
Disorganization	-0.14	-1.81	0.02	.07
Distress	0.38	5.03	0.14	<.0001
Quality of Life	-0.45	-3.63	0.18	.0006

Note: Analyses adjusted for age and age of psychosis onset.